US2008171033A1PendingUtilityA1

Compositions and methods for treating diseases associated with angiogenesis and inflammation

47
Assignee: CHANG CHIWENPriority: Aug 26, 2004Filed: Dec 24, 2007Published: Jul 17, 2008
Est. expiryAug 26, 2024(expired)· nominal 20-yr term from priority
Inventors:Chiwen Chang
A61P 37/00A61P 35/04A61P 35/00A61P 43/00A61P 27/02A61P 29/00C07K 16/2896A61K 2039/505A61P 19/02C07K 14/70596A61P 17/06
47
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Pharmaceutical compositions and methods for treating diseases associated with angiogenesis and inflammation. The invention relates to a pharmaceutical composition that includes a therapeutically effective amount of sCD26 and/or a biologically active derivative thereof and a pharmaceutically acceptable carrier. The composition may further include a therapeutically effective amount of sFlt-1 and/or a biologically active derivative thereof. Additionally, the invention relates to methods for treating a disease associated with and/or progresses by an inflammatory cytokine-associated inflammation and/or VEGF-associated angiogenesis.

Claims

exact text as granted — not AI-modified
1 . A pharmaceutical composition comprising:
 a. a therapeutically effective amount of sCD26; and   b. a pharmaceutically acceptable carrier.   
     
     
         2 . The pharmaceutical composition of  claim 1 , further comprising a therapeutically effective amount of sFlt-1 thereof. 
     
     
         3 . A method of treating a disease which is associated with and/or progresses by a biological activity of an inflammatory cytokine, comprising the step of administering to a mammalian subject, who would benefit therefrom, the pharmaceutical composition of  claim 1 . 
     
     
         4 . The method of  claim 3 , wherein the disease is associated with an increased Interleukin activity. 
     
     
         5 . The method of  claim 3 , wherein the disease is associated with an increased IL-2 activity. 
     
     
         6 . The method of  claim 3 , wherein the disease is selected from a group consisting of a tumor and an inflammatory disease. 
     
     
         7 . The method of  claim 3 , wherein the disease is an inflammatory disease. 
     
     
         8 . The method of  claim 7 , wherein the inflammatory disease is selected from the group consisting of rheumatoid arthritis, macular degeneration, psoriasis, and diabetic retinopathy. 
     
     
         9 . The method of  claim 3  wherein the disease is selected from the group consisting of a solid tumor, a tumor progression, tumor metastasis, and a latent tumor in a prevascular phase. 
     
     
         10 . A method of treating a disease which is associated with and/or progresses by VEGF-associated angiogenesis and an inflammatory cytokine-associated inflammation, comprising the step of administering to a mammalian subject, who would benefit therefrom, the pharmaceutical composition of  claim 2 . 
     
     
         11 . The method of  claim 10 , wherein the disease is selected from a group consisting of a tumor and an inflammatory disease. 
     
     
         12 . The method of  claim 11 , wherein the inflammatory disease is selected from the group consisting of rheumatoid arthritis, macular degeneration, psoriasis, and diabetic retinopathy. 
     
     
         13 . The method of  claim 10 , wherein the disease is selected from the group consisting of a solid tumor, tumor progression, tumor metastasis, and latent tumor in a prevascular phase. 
     
     
         14 . A method of treating a disease in which the morbid state progresses by a biological activity of an inflammatory cytokine, comprising the step of administering to a mammalian subject, who would benefit therefrom, the pharmaceutical composition of  claim 1 . 
     
     
         15 . The method of  claim 14 , wherein the disease is selected from the group consisting of a tumor and an inflammatory disease. 
     
     
         16 . The method of  claim 15 , wherein the inflammatory disease is selected from the group consisting of rheumatoid arthritis, macular degeneration, psoriasis, and diabetic retinopathy. 
     
     
         17 . The method of  claim 14 , wherein the disease is selected from the group consisting of a solid tumor, tumor progression, tumor metastasis, and latent tumor in a prevascular phase. 
     
     
         18 . The method of  claim 14 , wherein the disease is associated with an increased Interleukin activity. 
     
     
         19 . The method of  claim 14 , wherein the disease is associated with an increased IL-2 activity. 
     
     
         20 . A method of treating a disease in which the morbid state progresses by VEGF-associated angiogenesis and inflammatory cytokine-associated inflammation, comprising the step of administering to a mammalian subject, who would benefit therefrom, the pharmaceutical composition of  claim 2 . 
     
     
         21 . The method of  claim 20 , wherein the disease is selected from the group consisting of a tumor and an inflammatory disease. 
     
     
         22 . The method of  claim 20 , wherein the disease is selected from the group consisting of a solid tumor, a tumor progression, tumor metastasis, and a latent tumor in a prevascular phase. 
     
     
         23 . The method of  claim 21 , wherein the inflammatory disease is selected from the group consisting of rheumatoid arthritis, macular degeneration, psoriasis, and diabetic retinopathy. 
     
     
         24 . A method of inhibiting a biological activity of an inflammatory cytokine on a living cell comprising the step of providing the cell with a composition according to  claim 1 . 
     
     
         25 . The method of  claim 24 , wherein the cytokine contains a motif XP, in which X is an amino acid and P is proline. 
     
     
         26 . The method of  claim 24 , wherein the cytokine is IL-2. 
     
     
         27 . The method of  claim 24 , wherein the cell is present in a mammalian subject, who would benefit from the inhibition of the biological activity of an inflammatory cytokine. 
     
     
         28 . The method of  claim 27 , wherein the subject is suffering from a disease associated with and/or progressed by the biological activity of the inflammatory cytokine. 
     
     
         29 . The method of  claim 27 , wherein the disease is selected from the group consisting of a tumor and an inflammatory disease. 
     
     
         30 . The method of  claim 29 , wherein the disease is selected from the group consisting of rheumatoid arthritis, macular degeneration, psoriasis, and diabetic retinopathy. 
     
     
         31 . The method of  claim 27 , wherein the disease is selected from the group consisting of a solid tumor, tumor progression, tumor metastasis, and latent tumor in a prevascular phase. 
     
     
         32 . A method of inhibiting VEGF-associated angiogenesis and an inflammatory cytokine-associated inflammation comprising the step of administering to a mammalian subject, who would benefit therefrom, the pharmaceutical composition of  claim 2 .

Join the waitlist — get patent alerts

Track US2008171033A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.